Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone

Table 1

Comparison of the baseline data.

	Control group (n = 40)	Study group (n = 40)	t/χ^2
Age (, years)	54.55 ± 12.36	56.18 ± 14.02	0.550	0.584
Gender (n)			0.205	0.651
Male	16	18
Female	24	22
Course of disease (, months)	16.25 ± 4.46	15.03 ± 3.26	1.401	0.165
CTV of resection	1.78 ± 0.42	1.81 ± 0.54	0.275	0.784
KPS scores	77.31 ± 10.82	79.11 ± 11.45	0.721	0.473
Pathological types			0.572	0.751
Prolactinoma	14	11
Acromegaly	16	17
Cushing’s disease	10	12

CTV, clinical tumor volume.